title: Protective effects of silybin and tetrandrine on the outcome of spontaneously hypertensive rats subjected to acute coronary artery occlusion.
abstract: The effects of silybin and tetrandrine on the survival of spontaneously hypertensive rats subjected to acute coronary artery occlusion were investigated. The mortality after acute coronary occlusion in spontaneously hypertensive rats (66.7%) was higher than that of control Wistar-Kyoto rats (20%, P < 0.05). Oral administration of silybin (300 mg/kg daily) for 8-12 days reduced mortality in spontaneously hypertensive rats (0, P < 0.01 in comparison with untreated spontaneously hypertensive rats). Administration of tetrandrine 40 mg/kg daily for 8-12 days reduced the mortality to some extent (22.2%, P = 0.051, as compared with control rats). Silybin reduced blood pressure and the incidence of post-occlusion arrhythmias in spontaneously hypertensive rats to the same extent as tetrandrine. Both silybin and tetrandrine decreased the severity of ventricular hypertrophy. Although there were significant decreases in risk zone and infarct zone in silybin- and tetrandrine-treated rats, the ratio of infarct to risk zone was not changed. The results implies that silybin may be beneficial when used in hypertensive patients who develop acute myocardial infarction.
authors.affiliation: Department of Pharmacology, Changhai Hospital, Second Military Medical University, Shangahi, China.
authors.forename: H
authors.initials: H
authors.lastname: Chen
authors.forename: S C
authors.initials: SC
authors.lastname: Chen
authors.forename: T H
authors.initials: TH
authors.lastname: Zhang
authors.forename: H C
authors.initials: HC
authors.lastname: Tian
authors.forename: Y
authors.initials: Y
authors.lastname: Guan
authors.forename: D F
authors.initials: DF
authors.lastname: Su
mesh_terms: D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001145:Arrhythmias, Cardiac / Q000473:pathology / Q000503:physiopathology*; D044182:Benzylisoquinolines; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D003326:Coronary Circulation / Q000502:physiology; D016757:Death, Sudden, Cardiac / Q000473:pathology; D004562:Electrocardiography / Q000187:drug effects; D006973:Hypertension / Q000473:pathology / Q000503:physiopathology*; D017379:Hypertrophy, Left Ventricular / Q000473:pathology / Q000503:physiopathology*; D008297:Male; D009203:Myocardial Infarction / Q000473:pathology / Q000503:physiopathology*; D009206:Myocardium / Q000473:pathology; D009336:Necrosis; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D012838:Silymarin / Q000494:pharmacology*; D017180:Tachycardia, Ventricular / Q000473:pathology / Q000503:physiopathology; D014693:Ventricular Fibrillation / Q000473:pathology / Q000503:physiopathology
chemical_list: D000470:Alkaloids; D000959:Antihypertensive Agents; D044182:Benzylisoquinolines; D002121:Calcium Channel Blockers; D012838:Silymarin; C009438:tetrandrine